Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism

被引：19

作者：

Miller, Kena C.

Padmanabhan, Swaminathan

Dimicelli, Laurie

Depaolo, Dawn

Landrigan, Beverly

Yu, Jihnhee

Doran, Virginia

Marshal, Patricia

Chanan-Khan, Asher

机构：

[1] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA

[2] SUNY Buffalo, Dept Biostat, Buffalo, NY 14214 USA

来源：

LEUKEMIA & LYMPHOMA | 2006年 / 47卷 / 11期

关键词：

thromboemobolism; warfarin; thalidomide; leukemia;

D O I：

10.1080/10428190600799631

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Venous thromboemobolism (VTE) is an important complication of thalidomide therapy especially when it is combined with steroids or chemotherapy. Currently there is no consensus on the most appropriate prophylactic approach. We prospectively investigated the use of low-dose warfarin sodium in prevention of thalidomide-associated VTE in patients receiving thalidomide-based combination therapies. Patients with multiple myeloma or chronic lymphocytic leukemia who were treated on thalidomide based-combination therapies were treated on low-dose warfarin (1 or 2 mg) continuously through the duration of their therapy. Among the 68 patients enrolled, four developed an episode of VTE, an overall incidence of 5.9% (odds = 0.063). Median duration of thalidomide therapy was 4 months. Low-does warfarin decreases the incidence of VTE compared to historical control and is an effective mechanism of prevention of VTE in thalidomide-based chemotherapy regimens.

引用

收藏

页码：2339 / 2343

页数：5

相关论文

共 30 条

[1] Patient-specific factors predictive of warfarin dosage requirements [J].

Absher, RK ;

Moore, ME ;

Parker, MH .

ANNALS OF PHARMACOTHERAPY, 2002, 36 (10) :1512-1517

[2] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].

Barlogie, B ;

Desikan, R ;

Eddlemon, P ;

Spencer, T ;

Zeldis, J ;

Munshi, N ;

Badros, A ;

Zangari, M ;

Anaissie, E ;

Epstein, J ;

Shaughnessy, J ;

Ayers, D ;

Spoon, D ;

Tricot, G .

BLOOD, 2001, 98 (02) :492-494

[3]

Baz R, 2004, BLOOD, V104, p658A

[4] Thalidomide-associated deep vein thrombosis and pulmonary embolism [J].

Bennett, CL ;

Schumock, GT ;

Desai, AA ;

Kwaan, HC ;

Raisch, DW ;

Newlin, R ;

Stadler, W .

AMERICAN JOURNAL OF MEDICINE, 2002, 113 (07) :603-606

[5] VERY LOW-DOSES OF WARFARIN CAN PREVENT THROMBOSIS IN CENTRAL VENOUS CATHETERS - A RANDOMIZED PROSPECTIVE TRIAL [J].

BERN, MM ;

LOKICH, JJ ;

WALLACH, SR ;

BOTHE, A ;

BENOTTI, PN ;

ARKIN, CF ;

GRECO, FA ;

HUBERMAN, M ;

MOORE, C .

ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :423-428

[6] Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies [J].

Boraks, P ;

Seale, J ;

Price, J ;

Bass, G ;

Ethell, M ;

Keeling, D ;

Mahendra, P ;

Baglin, T ;

Marcus, R .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (03) :483-486

[7]

Bowcock Stella J, 2002, Hematology, V7, P51, DOI 10.1080/10245330290020126

[8] Thalidomide in multiple myeloma: Current status and future prospects [J].

Cavenagh, JD ;

Oakervee, H .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (01) :18-26

[9] Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy [J].

Cavo, M ;

Zamagni, E ;

Cellini, C ;

Tosi, P ;

Cangini, D ;

Cini, M ;

Valdrè, L ;

Palareti, G ;

Masini, L ;

Tura, S ;

Baccarani, M .

BLOOD, 2002, 100 (06) :2272-2273

[10] Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL) [J].

Chanan-Khan, A ;

Miller, KC ;

Takeshita, K ;

Koryzna, A ;

Donohue, K ;

Bernstein, ZP ;

Mohr, A ;

Klippenstein, D ;

Wallace, P ;

Zeldis, JB ;

Berger, C ;

Czuczman, MS .

BLOOD, 2005, 106 (10) :3348-3352